//
Luis A. Diaz
Hao Wang
Bjarne Bartlett
Holly Kemberling
Aleksandra Eyring
Nilofer Saba Azad
Tianna Dauses
Dan Laheru
James J. Lee
Todd S. Crocenzi
Richard M. Goldberg
George A. Fisher
Tim F. Greten
Christian Frederick Meyer
Amanda Nickles Fader
Deborah Kay Armstrong
Minori Koshiji
Bert Vogelstein
Dung T. Le
Johns Hopkins University, Baltimore, MD
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD
Johns Hopkins University School of Medicine, Baltimore, MD
University of Pittsburgh, Pittsburgh, PA
Providence Cancer Center, Portland, OR
The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH
National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Johns Hopkins, Baltimore, MD
The Johns Hopkins Hospital, Baltimore, MD
Merck & Co. Inc., Rahway, NJ
Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, Baltimore, MD
United States
Merck & Co., Inc.
N/A
N/A
Programmed cell death protein 1
Pembrolizumab
N/A
N/A
II
NCT01876511
N/A
Final